Skip to main content
Natalia R. Kunst on Muck Rack

Natalia R. Kunst

As seen in: Wiley Online Library, Applied Health Economics and Health Policy, JAMA (The Journal of the American Medical Association), Routledge, Cancer Epidemiology, Biomarkers & Prevention, HemOnc Today, The Journal of Allergy & Clinical Immunology, Journal of Nuclear Medicine, UroToday, Value in Health Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Natalia R.

Contact Natalia R., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cost-Effectiveness Analysis of 177Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective - Beyond the Abstract

|
By Kemal C. Gogebakan, Natalia R. Kunst, Alireza Ghodsi
| UroToday Verified
177Lu-PSMA-617 has emerged as a promising radiopharmaceutical therapy for metastatic castration-resistant prostate cancer (mCRPC), offering improved progression-free survival and quality of life compared with cabazitaxel in the TheraP trial. However, its substantially higher cost raises important questions about value within the US healthcare system.
Open in Who Shared Issue with article?

Cost-Effectiveness Analysis of 177 Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective

|
By Kemal C. Gogebakan, Natalia R. Kunst, Alireza Ghodsi
| Journal of Nuclear Medicine Verified
The TheraP trial demonstrated that 177Lu-PSMA-617 improved progression-free survival (PFS) compared with cabazitaxel, with no significant difference in overall survival (OS). However, 177Lu-PSMA-617 was associated with fewer severe adverse events, better patient-reported outcomes, and lower health care utilization rates. In this study, we evaluated the impact of these benefits on the cost-effectiveness of 177Lu-PSMA-617 versus cabazitaxel from a U.S. health care perspective.
Open in Who Shared Issue with article?

Cost‐effectiveness of low‐dose CT lung cancer screening among individuals that have ever smoked in Norway: A model‐based analysis using NELSON trial criteria and outcomes

|
By Natalia R. Kunst, Ivar Sønbø Kristiansen, Trond-Eirik Strand, Yancy S. Wu
| Wiley Online Library Verified
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. Supporting Information Filename Description ijc70270-sup-0001-supinfo.pdfPDF document, 917.9 KB Table S1. Number of the TIDL survey sent, total number responded, and number of respondents eligible for screening. Table S2.
Open in Who Shared Issue with article?
See all 17 licensed articles (22 Total)